Agennix falls on severe sepsis data

Agennix AG (Xetra:AGX) fell EUR 0.81 (30%) to EUR 1.88 on Thursday after talactoferrin plus standard of care led to an increased 28-day all-cause mortality, the primary endpoint, compared to standard of care alone in the Phase II/III OASIS trial in severe sepsis patients. Agennix, which stopped the trial, said it is unblinding the data to better understand the results. It will determine next steps after completing its review. Standard of care consisted of the Surviving Sepsis Campaign guidelines, which may include: IV blood pressure maintenance; medications to treat the infection; oxygen therapy; mechanical ventilation; nutritional support; and corticosteroid therapy. ...